The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Plasmodium vivax Invasion of Human Erythrocytes Inhibited by Antibodies Directed against the Duffy Binding Protein
Open accessAbstract
BACKGROUND: Plasmodium vivax invasion requires interaction between the human Duffy antigen on the surface of erythrocytes and the P. vivax Duffy binding protein (PvDBP) expressed by the parasite. Given that Duffy-negative individuals are resistant and that Duffy-negative heterozygotes show reduced susceptibility to blood-stage infection, we hypothesized that antibodies directed against region two of P. vivax Duffy binding protein (PvDBPII) would inhibit P. vivax invasion of human erythrocytes. METHODS AND FINDINGS: Using a recombinant region two of the P. vivax Duffy binding protein (rPvDBPII), polyclonal antibodies were generated from immunized rabbits and affinity purified from the pooled sera of 14 P. vivax-exposed Papua New Guineans. It was determined by ELISA and by flow cytometry, respectively, that both rabbit and human antibodies inhibited binding of rPvDBPII to the Duffy antigen N-terminal region and to Duffy-positive human erythrocytes. Additionally, using immunofluorescent microscopy, the antibodies were shown to attach to native PvDBP on the apical end of the P. vivax merozoite. In vitro invasion assays, using blood isolates from individuals in the Mae Sot district of Thailand, showed that addition of rabbit anti-PvDBPII Ab or serum (antibodies against, or serum containing antibodies against, region two of the Plasmodium vivax Duffy binding protein) (1:100) reduced the number of parasite invasions by up to 64%, while pooled PvDBPII antisera from P. vivax-exposed people reduced P. vivax invasion by up to 54%. CONCLUSIONS: These results show, for what we believe to be the first time, that both rabbit and human antibodies directed against PvDBPII reduce invasion efficiency of wild P. vivax isolated from infected patients, and suggest that a PvDBP-based vaccine may reduce human blood-stage P. vivax infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emergence of FY*A null in a Plasmodium vivax -endemic region of Papua New Guinea
Zimmerman, P. A., Woolley, I., Masinde, G. L., Miller, S. M., McNamara, D. T., Hazlett, F., Mgone, C. S., Alpers, M. P., Genton, B., Boatin, B. A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13973 · Cited by 231
Self-citation
Cited by
Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria
Beeson, J. G., Drew, D. R., Boyle, M. J., Feng, G., Fowkes, F. J. I., & Richards, J. S. (2016) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuw001 · Cited by 362
A Research Agenda for Malaria Eradication: Vaccines
The malERA Consultative Group on Vaccines (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000398 · Cited by 264
Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax
Gruszczyk, J., Kanjee, U., Chan, L.-J., Menant, S., Malleret, B., Lim, N. T. Y., Schmidt, C. Q., Mok, Y.-F., Lin, K.-M., Pearson, R. D., et al. (2018) · Science · doi:10.1126/science.aan1078 · Cited by 212
Requena, P., Arévalo-Herrera, M., Menegon, M., Martínez-Espinosa, F. E., Padilla, N., Bôtto-Menezes, C., Malheiro, A., Hans, D., Castellanos, M. E., Robinson, L., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00163 · Cited by 13
Self-citation
Metadata
- Authors
- Grimberg, B. T., Udomsangpetch, R., Xainli, J., McHenry, A., Panichakul, T., Sattabongkot, J., Cui, L., Bockarie, M., Chitnis, C., Adams, J., Zimmerman, P. A., & King, C. L.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-12-18
- Volume
- 4
- Issue
- 12
- Pages
- e337
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2004268547
- Cited by
- 184
- References
- 1
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.